Evidence map›Paper›PMID 42490454›Full record

ArticleScience advances2026

Strain-specific epistasis shapes fitness landscapes of APOBEC3G antagonism by HIV-1 Vif proteins.

Caroline A Langley, Michelle Lilly, Harmit S Malik, Michael Emerman

Abstract read
In one paragraph

Article in Science advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

4 authors.

Caroline A LangleyMolecular and Cellular Biology Graduate Program, University of Washington, Seattle, WA, USA.ORCID 0000-0002-0459-0568
Michelle LillyDivision of Human Biology, Fred Hutchinson Cancer Center, Seattle, WA, USA.ORCID 0009-0007-4549-316X
Harmit S MalikDivision of Basic Science, Fred Hutchinson Cancer Center, Seattle, WA, USA.ORCID 0000-0001-6005-0016
Michael EmermanDivision of Human Biology, Fred Hutchinson Cancer Center, Seattle, WA, USA.ORCID 0000-0002-4181-6335

Funding

Project 3U54AI170792 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Nevan J Krogan · 2022 to 2026
$35.7M
TRAINING IN MOLECULAR AND CELLULAR BIOLOGYT32GM007270 · NIGMS · UNIVERSITY OF WASHINGTON · PI RAIBLE, DAVID W · 1985 to 2020
$21.0M
NIAID NIH HHS U54 AI170792NIGMS NIH HHS T32 GM007270
6 · The paper itself

Abstract

Host immune factors shape viral evolution. The HIV-1 viral infectivity factor (Vif) protein counteracts host Apolipoprotein B Messenger RNA Editing Enzyme Catalytic Polypeptide-like 3 (A3G) to ensure productive infection. Using deep mutational scanning across two divergent HIV-1 Vif proteins, we systematically mapped and compared the mutational landscapes governing Vif antagonism of A3G. These high-resolution fitness maps reveal core principles of host-virus coevolution. Most missense mutations were strongly deleterious, reflecting pervasive purifying selection. However, several highly conserved Vif residues at binding interfaces with A3G, RNA, and core-binding factor β exhibited unexpected mutational tolerance, indicating structural flexibility at these sites. Comparative analysis revealed that strain-specific epistasis dictates Vif-A3G interactions, including adaptive changes at the Vif-A3G interface. Further analysis uncovered notable temporal epistasis, whereby initially adaptive Vif mutations critical for antagonizing hominoid A3G subsequently exhibited reduced fitness. Thus, structural robustness permits adaptation, while epistasis imposes constraints on Vif's ability to maintain A3G antagonism while remaining responsive to new evolutionary pressures.

Indexed as

APOBEC-3G DeaminaseEpistasis, GeneticGenetic FitnessHIV-1vif Gene Products, Human Immunodeficiency VirusEvolution, MolecularHost-Pathogen InteractionsHumansMutationProtein BindingAPOBEC-3G DeaminaseAPOBEC3G protein, humanvif Gene Products, Human Immunodeficiency Virusvif protein, Human immunodeficiency virus 1

Identifiers

PMID42490454
PMCPMC13394466

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.